Literature DB >> 18703118

Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn.

G Pollonini1, V Gao, A Rabe, S Palminiello, G Albertini, C M Alberini.   

Abstract

Down syndrome (DS) results from triplication of the whole or distal part of human chromosome 21. Persons with DS suffer from deficits in learning and memory and cognitive functions in general, and, starting from early development, their brains show dendritic and spine structural alterations and cell loss. These defects concern many cortical brain regions as well as the hippocampus, which is known to play a critical role in memory and cognition. Most of these abnormalities are reproduced in the mouse model Ts65Dn, which is partially trisomic for the mouse chromosome 16 that is homologous to a portion of human chromosome 21. Thus, Ts65Dn is widely utilized as an animal model of DS. To better understand the molecular defects underlying the cognitive and particularly the memory impairments of DS, we investigated whether the expression of several molecules known to play critical roles in long-term synaptic plasticity and long-term memory in a variety of species is dysregulated in either the neonatal brain or adult hippocampus of Ts65Dn mice. We found abnormal expression of the synaptic proteins synaptophysin, microtubule-associated protein 2 (MAP2) and cyclin-dependent kinase 5 (CDK5) and of the neurotrophin-3 (NT-3). Both the neonatal brain and adult hippocampus revealed significant abnormalities. These results suggest that a dysregulation in the expression of neurotrophins as well as proteins involved in synaptic development and plasticity may play a potential role in the neural pathology of DS in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703118      PMCID: PMC2613315          DOI: 10.1016/j.neuroscience.2008.07.025

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  70 in total

Review 1.  Role of Cdk5 in neuronal signaling, plasticity, and drug abuse.

Authors:  James A Bibb
Journal:  Neurosignals       Date:  2003 Sep-Oct

Review 2.  Cdk5: a novel role in learning and memory.

Authors:  André Fischer; Farahnaz Sananbenesi; Joachim Spiess; Jelena Radulovic
Journal:  Neurosignals       Date:  2003 Sep-Oct

Review 3.  Pre- and post-synaptic mechanisms regulating the clustering of type A gamma-aminobutyric acid receptors (GABAA receptors).

Authors:  J-M Fritschy; C Schweizer; I Brünig; B Lüscher
Journal:  Biochem Soc Trans       Date:  2003-08       Impact factor: 5.407

Review 4.  Synaptic trafficking of glutamate receptors by MAGUK scaffolding proteins.

Authors:  Guillermo M Elias; Roger A Nicoll
Journal:  Trends Cell Biol       Date:  2007-07-20       Impact factor: 20.808

5.  The in vivo phosphorylation sites of rat brain dynamin I.

Authors:  Mark E Graham; Victor Anggono; Nicolai Bache; Martin R Larsen; George E Craft; Phillip J Robinson
Journal:  J Biol Chem       Date:  2007-03-20       Impact factor: 5.157

6.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.

Authors:  Fabian Fernandez; Wade Morishita; Elizabeth Zuniga; James Nguyen; Martina Blank; Robert C Malenka; Craig C Garner
Journal:  Nat Neurosci       Date:  2007-02-25       Impact factor: 24.884

7.  The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome.

Authors:  Jesse E Hanson; Martina Blank; Ricardo A Valenzuela; Craig C Garner; Daniel V Madison
Journal:  J Physiol       Date:  2006-12-07       Impact factor: 5.182

8.  Quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome.

Authors:  Dong P Liu; Cecilia Schmidt; Timothy Billings; Muriel T Davisson
Journal:  Biotechniques       Date:  2003-12       Impact factor: 1.993

Review 9.  Cdk5: a new player at synapses.

Authors:  Kai Cheng; Nancy Y Ip
Journal:  Neurosignals       Date:  2003 Sep-Oct

10.  Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.

Authors:  Jonathan C Cruz; Huang-Chun Tseng; Joseph A Goldman; Heather Shih; Li-Huei Tsai
Journal:  Neuron       Date:  2003-10-30       Impact factor: 17.173

View more
  19 in total

1.  Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome.

Authors:  Ananya Mitra; Martina Blank; Daniel V Madison
Journal:  Brain Res       Date:  2012-01-03       Impact factor: 3.252

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

3.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

Review 4.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

5.  Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice.

Authors:  Melissa J Alldred; Sang Han Lee; Eva Petkova; Stephen D Ginsberg
Journal:  J Comp Neurol       Date:  2014-08-30       Impact factor: 3.215

6.  Normal protein composition of synapses in Ts65Dn mice: a mouse model of Down syndrome.

Authors:  Fabian Fernandez; Jonathan C Trinidad; Martina Blank; Dong-Dong Feng; Alma L Burlingame; Craig C Garner
Journal:  J Neurochem       Date:  2009-04-22       Impact factor: 5.372

7.  Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).

Authors:  Melissa J Alldred; Sang Han Lee; Eva Petkova; Stephen D Ginsberg
Journal:  Brain Struct Funct       Date:  2014-07-17       Impact factor: 3.270

8.  Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome.

Authors:  Fiorenza Stagni; Jacopo Magistretti; Sandra Guidi; Elisabetta Ciani; Chiara Mangano; Laura Calzà; Renata Bartesaghi
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

9.  Increased synaptophysin is involved in inflammation-induced heat hyperalgesia mediated by cyclin-dependent kinase 5 in rats.

Authors:  Hong-Hai Zhang; Xiao-Qin Zhang; Wen-Yuan Wang; Qing-Sheng Xue; Han Lu; Jin-Lu Huang; Ting Gui; Bu-Wei Yu
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

Review 10.  Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Authors:  Nicole Créau
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.